- Conditions
- Moderate to Severe Plaque Psoriasis
- Interventions
- bimekizumab
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Cypress, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Plaque Psoriasis, Scalp Psoriasis
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 79
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 67 more
- Conditions
- Psoriasis
- Interventions
- Clobetasol Propionate 0.05% Spray, Clobetasol Propionate 0.05% Foam
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 2
- States / cities
- Vallejo, California • St Louis, Missouri
- Conditions
- Psoriasis
- Interventions
- LD-Aminopterin oral capsule, Placebo oral capsule
- Drug
- Lead sponsor
- Syntrix Biosystems, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Seattle, Washington • Spokane, Washington
- Conditions
- Psoriasis, Pregnancy
- Interventions
- Not listed
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Morrisville, North Carolina
- Conditions
- Plaque Psoriasis
- Interventions
- Apo805K1
- Drug
- Lead sponsor
- ApoPharma
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Dallas, Texas • Houston, Texas + 1 more
- Conditions
- Chronic Plaque Type Psoriasis
- Interventions
- AIN457 300 mg, ustekinumab 45/90 mg, placebo secukinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 676 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more
- Conditions
- Psoriasis, Plaque Psoriasis, Insulin Resistance, PreDiabetes, Overweight and Obesity
- Interventions
- Oral glucose tolerance test (OGTT), Skin punch biopsy
- Diagnostic Test · Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Psoriasis
- Interventions
- Placebo (fasted), BI 25 mg (fasted), BI 50 mg (fasted), BI 100 mg (fasted), BI 200 mg (fasted), Placebo (fed), BI 400 mg once daily (fed), BI 200 mg twice daily, 400 mg total (fed)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 13 more
- Conditions
- Psoriasis
- Interventions
- peficitinib, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Diego, California • Miami, Florida + 8 more
- Conditions
- Plaque Psoriasis
- Interventions
- JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib, Deucravacitinib Matching Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 774 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 45 more
- Conditions
- Psoriasis
- Interventions
- Skin biopsy and blood test
- Procedure
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- ICD10 Code L40.9 for Psoriasis
- Interventions
- Betamethasone dipropionate 0.05%, Tapinarof
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Moderate to Severe Nail Psoriasis
- Interventions
- Secukinumab, Placebo
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Skokie, Illinois + 6 more
- Conditions
- Arthritis, Rheumatoid, Crohn Disease, Psoriasis
- Interventions
- Infliximab (Remicade)
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,971 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 100
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 97 more
- Conditions
- Psoriasis
- Interventions
- etanercept
- Biological
- Lead sponsor
- Florida Academic Dermatology Centers
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Arthritis, Psoriatic
- Interventions
- Sonelokimab, Placebo
- Drug
- Lead sponsor
- MoonLake Immunotherapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 28
- States / cities
- Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 25 more
- Conditions
- Psoriasis
- Interventions
- adalimumab
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Buckner 13075 PI, Alabama • Scottsdale, Arizona + 57 more
- Conditions
- Psoriasis
- Interventions
- BMS-986322, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Encino, California • Fountain Valley, California + 15 more
- Conditions
- Palmoplantar Pustulosis (PPP)
- Interventions
- Spesolimab, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Beverly Hills, California • San Diego, California + 11 more
- Conditions
- Psoriasis, Psoriatic Plaque
- Interventions
- Daavlin 7 series 3 panel narrow band phototherapy home units, narrow band phototherapy clinic units
- Device
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 783 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 31 more
- Conditions
- Psoriasis
- Interventions
- Desoximetasone 0.25% spray
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 3
- States / cities
- Hot Springs, Arkansas • Albuquerque, New Mexico • Simpsonville, South Carolina
- Conditions
- Atopic Dermatitis (AD), Psoriasis (PsO)
- Interventions
- LPX-TI641, Placebo
- Drug
- Lead sponsor
- LAPIX Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Fargo, North Dakota • Dallas, Texas
- Conditions
- Psoriasis
- Interventions
- LY3316531 - IV, LY3316531 - SC, Placebo - IV
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland